Novel, Targeted Therapies
We are leaders in the scientific areas underpinning our two pipeline products: cirmtuzumab, an anti-ROR1 antibody, and TK216, a small molecule ets-family transcription factor inhibitor.
These two product candidates are focused on exciting novel targets that are uniquely expressed within cancer cells. With our academic partners, we are developing products that are made to attack very specific mechanisms cancer cells use to grow and metastasize. Our scientific approach focuses on attacking those pathways, which are not expressed in healthy cells, in order to inhibit cancer cell growth, while minimizing potential harm to healthy cells.
We are also working with a variety of therapeutic strategies to address different medical challenges. These include preclinical programs related to small molecules, antibodies, antibody-drug conjugates (ADCs), genetically modified effector immune cells such as chimeric antigen receptor T-cells (CAR-T), and bispecific antibodies.
With our internal expertise and a strong network of academic collaborations, we are uniquely positioned to identify new research discoveries, and help expedite them into clinical development.Partnership Opportunities